Whether BCP ALL cases with a del(11)(q23) are discovered or not has several important practical implications, particularly regarding the comparison of incidence rates and treatment outcome of the group of patients with 11q23 abnormalities between different therapy studies. The detection of cases with a del(11)(q23) obviously depends on the diagnostic procedures that are pursued in a clinical study as conventional cytogenetics or MLL FISH screening (that will independently reveal classic MLL translocations) will identify them, whereas screening solely for ETV6/RUNX1 with FISH or RT-PCR will miss them. Thus, the respective screening approach will not only determine the actual incidence rates of 11q23/ MLL abnormalities but also influence the overall and, in particular, the age-specific survival rates in this group of patients. As can be deduced from the results of our analysis, the inclusion or exclusion of such cases is certainly relevant, especially when considering that cases with a del(11)(q23) constitute, as shown herein, approximately one-third of all 11q23 abnormalities. Moreover, as virtually all cases appear to be ETV6/RUNX1 þ , they do not only belong to a very favorable genetic ALL subset that is mainly enrolled into the lower risk groups but also to a more favorable age group that in any case has a better prognosis, even in the 11q23 abnormality group itself.
Our finding that del(11)(q23) is a nonrandom and highly specific secondary aberration in ETV6/RUNX1
þ BCP ALL rather than a disease-relevant primary abnormality provides substantial evidence that among ALL cases with 11q23 abnormalities it constitutes a highly distinct and separate entity. Based thereon, we suggest that in future clinical ALL studies, cases with a cytogenetically evident del(11)(q23) may not anymore be evaluated together with the 11q23/MLL translocations, but in the first instance, screened for the ETV6/RUNX1 fusion gene. Lenalidomide (Revlimid) is an immunomodulatory drug that yields a high frequency of erythroid, pathologic, and cytogenetic response in patients with myelodysplastic syndromes (MDS) with an interstitial deletion of the long arm of chromosome 5 (del 5q). We report here the case of a patient with acute myeloid leukemia (AML) (acute panmyelosis with myelofibrosis) with chromosome 5q deletion who achieved a complete hematologic and cytogenetic remission with lenalidomide treatment. A previously healthy 55-year-old female presented in September 2005 with shortness of breath and severe fatigue.
Her physical exam was unremarkable, including a lack of palpable hepatosplenomegaly. Laboratory data revealed white blood cells (WBC) count 3.8 k/ul, hemoglobin (Hb) of 6.4 g/dl, and platelet count 381 k/ul. Inspection of the peripheral blood film revealed no leukoerythroblastic features. A bone marrow biopsy performed on 26 September 2005 (Figure 1a ) revealed 60% cellularity, atypical megakaryocytic hyperplasia, along with markedly increased reticulin fibrosis. No increased number of myeloblasts was detected. Cytogenetic studies were not performed. The patient was managed conservatively with weekly erythropoietin injections and red blood cell transfusions every 2-3 weeks. Over the subsequent months, she developed progressive thrombocytopenia accompanying the transfusiondependent anemia. On 16 December 2005, the platelet count was 84 k/ul, and a repeat bone marrow aspirate and biopsy (Figure 1b) revealed AML with 22% blasts; the trephine biopsy was hypercellular with severe reticulin fibrosis. Cytogenetic analysis was unsuccessful due to a lack of adequate metaphases. The patient continued conservative management, and was referred for stem cell transplant consultation. Over the next 3 months, the patient had worsening thrombocytopenia and neutropenia (platelets 49 k/ul and absolute neutrophil count 0.73 k/ul). A repeat bone marrow biopsy and aspirate on 14 April 2006 was insufficient for full morphologic analysis; however, cytogenetic analysis from the aspirated sample revealed 46, XX, del (5) (q13q33) in three of three metaphases.
On 10 May 2006, the patient began treatment with lenalidomide 10 mg/day. Baseline WBC count was 2.81 k/ul, Hb 7.2 g/dl, platelet count 49 k/ul. The lenalidomide was discontinued after 14 days due to worsening neutropenia (absolute neutrophil count (ANC) 0.04 k/ul) and thrombocytopenia (platelet count 12 k/ul). Supportive care with platelet transfusions and granulocyte colony stimulating factor (G-CSF) was initiated. On 15 June 2006, the platelet count was 29 k/ul, ANC was 0.7 k/ul, and lenalidomide was resumed at 5 mg/day. By 14 July 2006, the platelet count was 54 k/ul, ANC 1.5 k/ul, and Hb 9.2 g/dl. A bone marrow biopsy (Figure 1c ) revealed 30% cellularity, continued marked reticulin fibrosis, and blasts less than 5%. Cytogenetic analysis revealed 46,XX in all 20 metaphases examined. On 26 July 2006, platelets had increased to 130 k/ul, ANC 5.27 k/ul. The RBC transfusion interval had increased from once weekly at the time of lenalidomide initiation to biweekly. On 13 September 2006, blood counts normalized, and the patient has been transfusion independent for over 2 months (Table 1) .
Myelodysplastic syndrome associated with the 5q minus abnormality confers a favorable prognosis and high likelihood of clinical, pathologic, and cytogenetic response to lenalidomide.
1,2 In a multicenter trial of lenalidomide in low or lowintermediate risk MDS with del 5q, rates of transfusion independence and cytogenetic response were 66 and 74%, respectively. 2 Interestingly, the probability of hematologic and cytogenetic response to lenalidomide was independent of Letters to the Editor karyotype complexity, suggesting an important role for del 5q in the pathophysiology of the disease. Indeed, fluorescence in situ hybridization (FISH) studies performed in flow sorted marrow cell populations have shown that CD34 þ CD38 À primitive hematopoietic progenitors harbor the del 5q abnormality in patients with MDS, supporting the notion that the chromosome 5q deletion acts as an initiating or transforming event that penetrates the hematopoietic stem cell level. 3 In AML, the presence of del 5/5q is associated with an unfavorable prognosis and low rates of complete remission (CR) and survival. 4, 5 In addition, its presence is more common in older patients than in younger ones. 4, 6 Although the precise role of chromosome 5 deletion in the pathophysiology of AML remains to be elucidated, it is noteworthy that deletions of chromosome 5/5q occur frequently at diagnosis in alkylatingagent-related AML, suggesting that this molecular anomaly may be pathogenic in AML, 7, 8 and perhaps responsive to lenalidomide. The brisk clinical response to lenalidomide observed in this case supports further investigation of lenalidomide in other myeloid malignancies with del 5q, including acute leukemia, where del 5q may be pathogenic. Rearrangements of the MLL (mixed lineage leukemia) gene are associated with pediatric, adult and therapy-related acute leukemias of both myeloid (AML) and lymphoid lineage (ALL).
1,2 Today, 55 partner genes have been characterized at the molecular level and additional 36 genetic loci have been identified by cytogenetics. 3 The most common translocation partner genes are AFF1 (AF4), MLLT3 (AF9), MLLT1 (ENL), MLLT10 (AF10), MLLT4 (AF6) and ELL, respectively. These partner genes account for about 80% of all rearrangements of the MLL gene. 3, 4 The MLLT1 gene is a frequent translocation partner and accounts for about 5% of all MLL rearrangements. In most cases, the MLLT1 gene is rearranged with the MLL gene via a balanced reciprocal translocation, but also more complex aberrations have been described including three way translocations. [5] [6] [7] The t(11;19)(q23;p13.3) has been identified in patients with lymphoid, myeloid and biphenotypic malignancies. Therapy-related translocations between MLL and MLLT1 are very rare, and so far only one t-AML case has been described in the literature. 8 Although MLL rearrangements are associated with a dismal outcome, two distinct subsets within the group of MLL-MLLT1 fusions have been identified that seem to have a good prognosis: ALL patients between 1and 9 years and patients with T-lineage ALL.
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The MLLT1 gene encodes a protein with a high homology to the MLLT3 gene.
10,11 It has been shown that the DNA-binding motifs encoded by the MLL gene and the C-terminal domain of MLLT1 are necessary and sufficient for the transforming activity of the MLL-MLLT1 fusion protein.
12 Retroviral transduction of MLL-MLLT1 transgenes into hematopoietic progenitors was sufficient to cause leukemia in mice.
13,14 A translocator mouse model has also been developed in which de novo chromosomal translocations of the Mll and Mllt1 loci can be induced during hematopoietic development. 15 After induction of chromosomal translocations, a rapid development of myeloid leukemias has been observed. Moreover, the Mll-Mllt1 fusion protein was able to genetically instruct lymphoid progenitor cells to develop into myeloid cells, demonstrating that this Mll-Mllt1 fusion protein has the ability to influence hematopoietic lineage commitment. 16 The human MLL-MLLT1 fusion protein was shown to be required for the immortalization of murine myeloid progenitors by aberrantly sustaining a specific 'Hox code' which is reflected by the upregulation of the HoxA4-HoxA11 genes, respectively. 17 Here, we investigated the genomic breakpoints of 40 acute leukemia patients carrying the t(11;19)(q23;13.3) chromosomal translocation. Bone marrow or peripheral blood of 40 different leukemia patients were collected over a period of 2 years at different European study centers (Interfant-99, GMALL and I-BFM). The patients separate into 22 pediatric (ALL: 20; AML: 2) and 18 adult leukemia patients (ALL: 17; AML: 1). For all patients, the genomic fusions sites were successfully
